Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza raka jajnika opornego na chemię platynową (powrót choroby w ciągu 6 miesięcy po ostatniej chemioterapii)
- •Potwierdzenie histologiczne (badanie mikroskopowe) pierwotnego guza
- •Mierzalne zmiany nowotworowe widoczne w badaniach obrazowych lub fizycznym badaniu
- •Co najmniej jedno miejsce zmian dostępne do biopsji przed i podczas leczenia
- •Minimum 28 dni od zabiegu chirurgicznego przed włączeniem do badania
- •Nie więcej niż jedna wcześniejsza chemioterapia na raka opornego na chemię platynową
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (6)
The University of Chicago Medical Center
Chicago, United States
BCCA - Kelowna
Kelowna, Canada
BCCA - Vancouver
Vancouver, Canada
Odette Cancer Centre
Toronto, Canada
University Health Network
Toronto, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Canada
Trial contact
Janet Dancey
Pierre-Olivier Gaudreau
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.